Celcuity Inc. (CELC) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Minneapolis, MN, United States. वर्तमान CEO हैं Brian F. Sullivan.
CELC के पास है IPO तिथि 2017-09-20, 87 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Capital Marke, बाजार पूंजीकरण $5.84B.
Celcuity Inc. is a clinical-stage biotechnology company headquartered in Minneapolis, Minnesota, focused on developing molecularly targeted cancer therapies for patients in the United States. The company's proprietary CELsignia diagnostic platform analyzes living tumor cells to identify the specific cellular abnormalities driving a patient's cancer and determines the most appropriate targeted treatment approach. Its lead drug candidate, Gedatolisib, selectively targets PI3K and mTOR pathways and is being evaluated for treating hormone receptor-positive, HER2-negative advanced or metastatic breast cancer under a license agreement with Pfizer. Celcuity is also advancing the CELsignia MP test, a laboratory-developed diagnostic that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor samples to guide therapeutic selection.
